Show simple item record

dc.contributor.authorGerrard, Adam
dc.contributor.authorDawson, Charlotte
dc.date.accessioned2023-08-17T15:14:34Z
dc.date.available2023-08-17T15:14:34Z
dc.date.issued2022-09-19
dc.identifier.citationGerrard A, Dawson C. Homocystinuria diagnosis and management: it is not all classical. J Clin Pathol. 2022 Sep 19:jclinpath-2021-208029. doi: 10.1136/jcp-2021-208029. Epub ahead of printen_US
dc.identifier.issn0021-9746
dc.identifier.eissn1472-4146
dc.identifier.doi10.1136/jcp-2021-208029
dc.identifier.pmid36123115
dc.identifier.urihttp://hdl.handle.net/20.500.14200/1747
dc.description.abstractHomocystinuria (HCU) refers to a group of inherited disorders of homocysteine metabolism associated with high blood homocysteine concentration, thromboembolic tendency and neurocognitive symptoms. The most common causes of a high blood homocysteine relate to underlying vitamin B12 or folate deficiency which must be excluded first. Thereafter, an inherited metabolic condition can be considered.The most prevalent inherited disorder of homocysteine metabolism is classical HCU caused by deficiency of the pyridoxine-dependent enzyme, cystathione beta-synthase, which converts homocysteine to cystathionine in the transsulphuration pathway. An alternative route for homocysteine metabolism is its remethylation to methionine by the cobalamin-dependent enzyme, methionine synthase, using the folate derivative, methyltetrahydrofolate, as a methyl donor. Remethylation defects are caused by impaired activity of methionine synthase itself, of an enzyme required to generate its methylcobalamin cofactor from dietary vitamin B12, or of the enzyme methyltetrahydrofolate reductase (MTHFR), which generates the methyl donor.The correct diagnosis can be inferred from additional laboratory investigations including a complete blood count and quantitation of methionine and methylmalonic acid. Methionine is high/normal in HCU and low in the remethylation disorders. In the latter, cobalamin defects are readily distinguished from MTHFR by a coexisting macrocytic anaemia and further delineated by presence or absence of methylmalonic acid in urine or plasma.Lowering homocysteine reverses thromboembolic risk. In HCU, this may be achieved with pyridoxine alone or with betaine as an alternative methyl donor. Some patients additionally follow a methionine-restricted diet. Betaine is the primary treatment for MTHFR and cobalamin disorders are managed with high-dose hydroxocobalamin.en_US
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.urlhttp://jcp.bmj.com/en_US
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/journals/162/en_US
dc.rights© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
dc.subjectEndocrinologyen_US
dc.subjectClinical pathologyen_US
dc.titleHomocystinuria diagnosis and management: it is not all classical.en_US
dc.typeArticle
dc.source.journaltitleJournal of Clinical Pathology
dc.source.countryEngland
rioxxterms.versionNAen_US
dc.contributor.trustauthorDawson, Charlotte
dc.contributor.departmentEndocrinologyen_US
dc.contributor.roleMedical and Dentalen_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record